
    
      A 12-week, double-blind, placebo-controlled, multicenter, randomized study designed to
      evaluate the safety and efficacy of 40 mg/day istradefylline compared with placebo in
      subjects with OFF phenomena advanced PD who were treated with levodopa/carbidopa.
    
  